识别罕见的疾病相关基因的瓦里安ts in patients with severe schizophrenia

Schizophrenia patients have a diverse spectrum of observable symptoms. For this study, the researchers focused on the extreme end of that spectrum -- a group of 112 patients with severe, extremely treatment-resistant schizophrenia who have required long-term hospitalization in New York State inpatient facilities.

"The hypothesis is that these patients might have a greater prevalence of disease-causing mutations because they have such a severe form of the illness, and that's what we ended up seeing," said Zoghbi, corresponding author of the study and Beth K. And Stuart C. Yudofsky Scholar at Baylor.

Zoghbi and his team examined mutations across a set of "intolerant" genes, which are infrequently mutated in the healthy, general population. They conducted genetic sequencing and examined the burden of rare, damaging variants impacting gene function in three groups: people with severe schizophrenia, people with typical schizophrenia and a control group of healthy individuals.

超过48%的患者非常treatment-resistant schizophrenia carried at least one of the rare, damaging variants, versus approximately 30% of those with typical schizophrenia and 25% of the control group. The severe schizophrenia group also had a higher variant burden in genes previously associated with schizophrenia than the group with typical schizophrenia.

"We think that this method of study could be a new paradigm for trying to understand how to enrich a genetic signal in a psychiatric disorder by focusing on individuals who are very severely affected by the disease," said Zoghbi, who also is chief of psychiatric genetics in the Menninger Department of Psychiatry and Behavioral Sciences at Baylor.

Identifying rare variant risk factors in individuals with severe schizophrenia could lead to better understanding of prognosis and treatment resistance and to more opportunities for genetic counseling for families impacted by this disease. Zoghbi says this study also may lay the groundwork for future research on therapeutics to target genetic mutations associated with schizophrenia.

"We hope that this research brings light and attention to these patients who are often left out of cutting-edge research because of the severity of their condition," Zoghbi said.

Other authors of this work include: Dr. Ryan S. Dhindsa, Dr. Terry E. Goldberg, Aydan Mehralizade, Dr. Joshua E. Motelow, Dr. Xinchen Wang, Dr. Anna Alkelai, Dr. Matthew B. Harms, Dr. Jeffrey A. Lieberman, Dr. Sander Markx and Dr. David B. Goldstein. They are affiliated with the following institutions: Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, Columbia University Irving Medical Center, New York State Psychiatric Institute and Waypoint Bio.

The study is funded in part by the Chapman Perelman Foundation and the National Institute of Mental Health.